Omeros Co. (NASDAQ:OMER) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 12,840,000 shares, a growth of 17.5% from the August 15th total of 10,930,000 shares. Based on an average daily volume of 1,320,000 shares, the short-interest ratio is presently 9.7 days.

A number of equities analysts recently weighed in on OMER shares. BidaskClub raised shares of Omeros from a “strong sell” rating to a “sell” rating in a report on Friday, September 11th. HC Wainwright reduced their target price on shares of Omeros from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, August 21st. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Thursday, September 3rd. Maxim Group reduced their target price on shares of Omeros from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Wedbush lowered their price target on shares of Omeros from $17.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $19.75.

Shares of OMER stock traded up $0.52 during trading on Wednesday, hitting $12.79. The company had a trading volume of 56,341 shares, compared to its average volume of 921,918. The stock’s 50-day moving average is $12.71 and its two-hundred day moving average is $13.96. The stock has a market capitalization of $668.94 million, a price-to-earnings ratio of -6.24 and a beta of 1.66. Omeros has a 52 week low of $8.50 and a 52 week high of $25.46.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.02). The business had revenue of $13.53 million during the quarter, compared to analyst estimates of $18.12 million. On average, research analysts anticipate that Omeros will post -1.82 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in OMER. BlackRock Inc. increased its position in shares of Omeros by 4.0% during the first quarter. BlackRock Inc. now owns 4,224,878 shares of the biopharmaceutical company’s stock valued at $56,485,000 after buying an additional 162,255 shares during the period. SG Americas Securities LLC bought a new position in Omeros in the 1st quarter worth about $130,000. American International Group Inc. increased its stake in Omeros by 2.5% during the 1st quarter. American International Group Inc. now owns 30,285 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 727 shares in the last quarter. Aperio Group LLC purchased a new position in Omeros in the first quarter worth about $189,000. Finally, Arizona State Retirement System purchased a new position in Omeros in the first quarter worth about $148,000. Hedge funds and other institutional investors own 58.36% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Article: Are sell-side analysts objective?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.